Role of liver function tests in monitoring anticonvulsant use

CNS Drugs

Volumn 10, Issue 5, 1998, Pages 321-328

  Schmidt, Dieter ^a,c   Siemes, Hartmut ^a,b  

^a Epilepsy Research Group Berlin   (Germany)

^b DRK KLINIKEN BERLIN WESTEND   (Germany)

^c FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; ETHOSUXIMIDE; FELBAMATE; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENYTOIN; PROGABIDE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ANOREXIA; BLEEDING; DRUG MONITORING; EARLY DIAGNOSIS; EDEMA; HUMAN; JAUNDICE; LIVER DYSFUNCTION; LIVER FUNCTION TEST; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SCREENING; SEIZURE; VOMITING;

EID: 0031724894     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199810050-00002     Document Type: Review

References (47)

1. Jeavons PM, Clarke JE. Sodium valproate in the treatment of epilepsy. BMJ 1974; 2: 584-6
2. Loyning Y, Johannessen SI, Ritland LS, et al. Cases of serious/fatal hepatotoxicity due to valproate: recommended control scheme and preliminary results. In: Oxley J, Janz D, Meinardi H, editors. Chronic toxicity of antiepileptic drugs. New York: Raven, 1982: 47-70
3. Stenzel E, Albani M, Doose H, et al. Valproat-Therapie und Lebertoxizität. Pädiatr Prax 1987; 35: 159-63
4. Physicians desk reference. 51st ed. Montvale (NJ): Medical Economics Company, 1997
5. Pellock JM, Willmore LJ. A rational guide to routine blood monitoring in patients receiving antiepileptic drugs. Neurology 1991; 41: 961-4
6. Camfield C, Camfield P, Smith E, et al. Asymptomatic children with epilepsy: little benefit from screening anticonvulsant-induced liver, blood, or renal damage. Neurology 1996; 36: 838-41
7. Fenichel GM, Greene HL. Valproate hepatotoxicity: two new cases, a summary of others, and recommendations. Pediatr Neurol 1985; 1: 109-13
8. Erasmus C, Hjelm M, Wilson J. The value of routine liver function monitoring during sodium valproate therapy. Br J Clin Pract 1983: 727 Suppl.: 77-8
9. Silberstein SD, Willmore LJ. Divalproex scxlium: migraine treatment and monitoring. Headache 1996; 36 (4): 239-42
10. Callaghan N, Majeed T, O'Connell A, et al. A comparative study of serum F protein and other liver function tests as an index of hepatocellular damage in epileptic patients. Acta Neurol Scand 1994; 89 (4): 237-41
11. Schmidt D. Adverse effects of antiepileptic drugs. New York: Raven Press, 1982
12. Oxcarbazepine. Product monograph. Basle, Switzerland: Novartis, 1997
13. Topamax. Product monograph. Cilag International, 1996
14. Richens A. Lamotrigine: toxicity. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic drugs. 4th ed. New York: Raven, 1995: 897-902
15. Schmidt D, Shorvon S. The epilepsies. In: Brandt T, Caplan LR, Dichgans J, et al., editors. Neurological disorders: course and treatment. San Diego (CA): Academic Press, 1996: 159-82
16. König StA, Elger CE, Vassella F, et al. Empfehlungen zu Blutuntersuchungcn und klinischer Überwachung zur Früherkennung des Valproat-assoziierten Leberversagens. Nervenarzt. Schweiz Ärztezeitung 1998; 79 (14): 580-5
17. Morselli PL, Lloyd KG, Palminteri R, Progabide. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic drugs. 4th ed. New York: Raven, 1995: 997-1009
18. Schmidt D, Krämer G. The new antiepileplic drugs: implications for avoidance of adverse effects. Drug Saf 1994; 11: 422-31
19. Tiagabine. Product monograph. Mainz: Novo-Nordisk, 1997
20. Asconape JJ, Penry JK, Dreifuss FE, et al. Valproate-associated pancreatitis. Epilepsia 1993; 34: 177-83
21. Powell-Jackson PR, Tredger JM, Williams R. Hepatotoxicity to sodium valproate: a review. Gut 1984; 25: 673-81
22. Bryant AE, Dreifuss FE. Valproic acid hepatic fatalities: III. US experience since 1986. Neurology 1996; 46: 465-9
23. Dreifuss FE, Santilli N, Langer DH, et al. Valproic acid hepatic fatalities: a retrospective review. Neurology 1987; 37: 397-400
24. Dreifuss FE, Langer DH, Moline KA, et al. Valproic acid hepatic fatalities: III. US experience since 1984. Neurology 1989; 39: 201-7
25. Appleton RE, Farell K, Applegarth DA, et al. The high incidence of valproate hepatotoxicity may relate to familial metabolic defects. Can J Neurol Sci 1990; 17: 145-8
26. Harding BN, Egger J, Portmann B, et al. Progressive neuronal degeneration of childhood with liver disease. Brain 1986; 109: 181-206
27. Strassburg HM, Sauer M, Ketelsen UP, et al. Letale Valproat-Unverträglichkeit bei progressiver zerebraler Poliodystrophie Alpers. In: Lütschg J, editor. Aktuelle Neuropädiatrie 1990. Berlin: Springer, 1990: 258-63
28. Dodson WE. Discussion. In: Schmidt D, Perucca E, editors. The place of felbamate in the treatment of Lennox-Gastaut syndrome: an update [abstract]. Proceedings of a meeting; 1997 Apr 22-23: Düsseldorf. sHertogenbosch: Vanzuiden Comm, 1997: 8
29. Fisher RS, Kerrigan JF. Vigabatrin: toxicity. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic drugs. 4th ed. New York: Raven, 1995: 931-9
30. Data on file, Parke-Davis, 1993
31. Ramsay RE. Clinical efficacy and safety of gabapentin. Neurology 1994; 44 Suppl. 5: S23-30
32. Vigabatrin. Product monograph. Bad Soden: Hoechst Marion Roussell, 1997
33. Seino M, Naruto S, Ito T, et al. Zonisamide. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic drugs. 4th ed. New York: Raven, 1995: 1011-23
34. Jeavons PM. Hepatotoxicity of antiepileptic drugs. In: Oxley J, Janz D, Meinardi H. Chronic toxicity of antiepileptic drugs. New York: Raven, 1982: 1-45
35. Scheffner D, König StA, Rauterberg-Ruland I, et al. Fatal liver failure in 16 children with valproate therapy. Epilepsia 1988; 29: 530-42
36. Siemes H, Nau H, Seidel U, et al. Irreversibles valproat-assoziiertes Leberversagen. Monatsschr Kinderheilkd 1992; 140: 869-75
37. Suchy FJ, Balisteri WF, Buchino JJ, et al. Acute hepatic failure associated with the use of sodium valproate. N Engl J Med 1979; 300: 962-6
38. Zäh W, Rengeling M, Rühl G, et al. Akute Lebernekrose durch Valproinat. Dtsch Med Wochenschr 1985; 110: 956-9
39. O'Neil MG, Perdun CS, Wilson MB, et al. Felbamate-associated fatal acute hepatic necrosis. Neurology 1996; 46: 1457-9
40. Data on file. Kenilworth, USA: Schering-Plough, 1997
41. Zimmerman HJ, Ishak KG. Valproate-induced hepatic injury: analysis of 23 fatal cases. Hepatology 1982; 2: 591-7
42. Yuen AWC, Bihari DJ. Multi-organ failure and disseminated intravascular coagulation in severe convulsive seizures [letter]. Lancet 1992; 340: 618
43. Ussery XT, Henar EL, Black DD, et al. Acute liver injury after protracted seizures in children. Pediatr Gastroenterol 1989; 9: 421-5
44. Brown SW, Clarke MA, Tomlin PI. Fatal liver failure following generalized tonic-clonic seizures. Seizure 1992; 1: 75-7
45. Ware S, Milliward-Sadler GH. Acute liver disease associated with sodium valproate. Lancet 1980; II: 1110-3
46. Williams R. Hepatic disorders: discussion. In: Oxley J, Janz D, Meinardi H, editors. Chronic toxicity of antiepileptic drugs. New York: Raven Press, 1982: 79-84
47. Tredger JM, Sherwood RA. The liver: new functional, prognostic and diagnostic tests. Ann Clin Biochem 1997; 34: 121-41